Debug Stats | ### Total Build Time: 38 ms 39.717 KB CONCEPT_NAME gt=2 ms Completed: 2 ms rowSize= 332 bytesCONCEPT_SOLR_HIT_STATS gt=0 Completed: 0 ms rowSize= 14 bytesCONCEPT_DEFINITION gt=0 Completed: 0 ms rowSize= 216 bytes- Skipping details on:
CONCEPT_SYNONYM gt=NONE 0 Completed: 0 ms rowSize= 0 bytes - Skipping details on:
CONCEPT_TEXT gt=NONE 0 Completed: 0 ms rowSize= 0 bytes CONCEPT_SEMANTIC_TYPE gt=0 Completed: 0 ms rowSize= 14 bytes- Skipping details on:
CONCEPT_NAMESPACE gt=NONE 0 Completed: 0 ms rowSize= 0 bytes CONCEPT_PARENTS gt=0 Completed: 0 ms rowSize= 7 bytesCONCEPT_CHILDREN gt=0 Completed: 0 ms rowSize= 8 bytesCONCEPT_ANCESTRAL_ROOTS gt=0 Completed: 0 ms rowSize= 15 bytesCONCEPT_RELATIONSHIPS gt=1 ms Completed: 1 ms rowSize= 106 bytesCONCEPT_GENES gt=34 ms Completed: 34 ms rowSize= 37.856 KBCONCEPT_XREFS gt=1 ms Completed: 1 ms rowSize= 1.151 KBCONCEPT_ANCILLARY gt=0 Completed: 0 ms rowSize= 14 bytes- Reload Stats
|
Genes (138)
Species: human : 134 mouse : 4 | |
Mouse | HMGA2 | 8091 | high mobility group AT-hook 2 | Click here to display 5 evidence detail records. | Mouse | HMGA1 | 3159 | high mobility group AT-hook 1 | Transgenic mice overexpressing the wild-type form of the HMGA1 gene develop mixed growth hormone/prolactin cell pituitary adenomas and natural killer cell lymphomas. | Mouse | GHRH | 2691 | growth hormone releasing hormone | Excessive GHRH stimulation leads to somatotrope hyperplasia and, ultimately, pituitary adenoma formation in the metallothionein promoter-driven human GHRH (hGHRH) transgenic mouse. Autoradiographic demonstration of in vivo 125I-growth hormone-releasing hormone (GHRH) binding by human GH-secreting pituitary adenomas transplanted on athymic nude mice. | Mouse | CDKN2C | 1031 | cyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4) | Mice lacking both p18 and p27, like mice chimeric for Rb deficiency, invariably died from pituitary adenomas by 3 months. The p18-p21 double null mice, on the other hand, developed pituitary adenomas, multifocal gastric neuroendocrine hyperplasia, and lung bronchioalveolar tumors later in life. Mice deficient in CKI p18 or p27 develop intermediate lobe pituitary tumors, p21 deletion facilitates such tumor growth in Rb-deficient mice, and p18 expression is low in GH-secreting pituitary adenomas (3-6). p21 and p27 gene mutations have not been detected in pituitary tumors (7,8). | Human | MIR16-2 | 406951 | | miR-15a and miR-16-1 down-regulation in pituitary adenomas. | Human | MIR16-1 | 406950 | | We found that miR-15a and miR-16-1 are expressed at lower levels in pituitary adenomas as compared to normal pituitary tissue. miR-15a and miR-16-1 down-regulation in pituitary adenomas. | Human | LRIG3 | 121227 | leucine-rich repeats and immunoglobulin-like domains 3 | Down-regulation of LRIG3 in HP75 pituitary adenoma is reported | Human | INHBE | 83729 | inhibin, beta E | Click here to display 14 evidence detail records. | Human | CYSLTR2 | 57105 | cysteinyl leukotriene receptor 2 | We investigated the effects of hypothalamic neuropeptides acting via GPCR on this pathway in GH-secreting (GH-oma) and nonsecreting (NFPA) pituitary adenomas. In conclusion, this study demonstrated that in pituitary adenomas the activation of GPCR by neurohormones caused a PKC-dependent activation of ERK1/2 cascade that, at least in GH-omas, resulted to be involved in cyclin D1 induction by GHRH. | Human | MEG3 | 55384 | maternally expressed 3 (non-protein coding) | MEG3 may represent a novel growth suppressor, which may play an important role in the development of human pituitary adenomas Taken together, our data suggest that MEG3 may represent a novel growth suppressor, which may play an important role in the development of human pituitary adenomas. | Human | RHBDD3 | 25807 | rhomboid domain containing 3 | Although PTAG expression is significantly underexpressed in most pituitary adenomas, mechanisms in addition to methylation most likely account for its loss. | Human | NTSR2 | 23620 | neurotensin receptor 2 | NTR1 and NTR2 mRNA were not detected in either pituitary adenomas or normal tissue | Human | PTP4A3 | 11156 | protein tyrosine phosphatase type IVA, member 3 | The distribution of PRL-R mRNA in 28 pituitary adenomas was examined by in situ hybridization and reverse transcription-PCR in 12 cases of adenomas. | Human | COPS5 | 10987 | COP9 signalosome subunit 5 | No difference was found in Jab1 protein levels in either corticotroph tumors or other pituitary adenomas, compared with normal tissue, but there was a small but significant increase in Jab1 levels in carcinomas. Such variations in phosphorylation may play a role in pituitary tumorigenesis, but modulation of Jab1 is unlikely to be important in the pathogenesis of pituitary adenomas. In this study, we further explored the role of p27 in human pituitary tumors by measuring levels of phosphorylated p27 (P-p27), and also Jun activation domain-binding protein 1 (Jab1), which is thought to facilitate the phosphorylation and degradation of p27, in normal pituitary tissue (n = 21), pituitary adenomas (n = 75), and pituitary carcinomas (n = 10). | Human | SCGB1D2 | 10647 | secretoglobin, family 1D, member 2 | The present report demonstrates, for the first time, lipophilin B expression in the pituitary and its apparent down-regulation in pituitary adenomas | Human | SV2A | 9900 | synaptic vesicle glycoprotein 2A | In pituitary adenomas more cells were immunoreactive to SV2 than to the other two antibodies. | Human | PTTG1 | 9232 | pituitary tumor-transforming 1 | Click here to display 24 evidence detail records. | Human | EBAG9 | 9166 | estrogen receptor binding site associated, antigen, 9 | Immunohistochemical analysis of RCAS1 in human pituitary adenomas. These results suggest that expression of RCAS1 as well as MIB-1 positivity predict the growth potential of individual pituitary adenomas. Expression of RCAS1 was noted in 48% of pituitary adenomas immunohistochemically (60.0% of growth hormone-secreting adenomas, 60.0% of prolactin-secreting adenomas, 42.9% of adrenocorticotrophin-secreting adenomas, 40.0% of thyroid-stimulating hormone-secreting adenomas, 33.3% of nonfunctioning adenomas, and 44.4% of gonadotropin-subunit-positive adenomas). This immunohistochemical study is aimed to elucidate the expression of RCAS1 in human pituitary adenomas in order to clarify its role in their proliferative regulation and invasiveness. | Human | AIP | 9049 | aryl hydrocarbon receptor interacting protein | Click here to display 7 evidence detail records. | Human | SOCS1 | 8651 | suppressor of cytokine signaling 1 | The data is compatible with epigenetic silencing of the SOCS-1 gene and constitutive activation of the JAK-STAT pathway in pituitary adenomas | Human | HMGA2 | 8091 | high mobility group AT-hook 2 | Click here to display 8 evidence detail records. | Human | SCG2 | 7857 | secretogranin II | Positive rate of chromogranin A was 40.0% and chromogranin C was positive in 8.0% of 45 pituitary adenomas. In the present report, a specific hSgII antiserum was used in immunohistochemistry experiments to determine the distribution of SgII in normal anterior pituitaries and pituitary adenomas (5 gonadotroph, 3 non-functioning and 5 mammotroph tumors). | Human | CXCR4 | 7852 | chemokine (C-X-C motif) receptor 4 | CXCR4 and SDF1 are overexpressed in human pituitary adenomas | Human | VEGFC | 7424 | vascular endothelial growth factor C | The VEGF-C system may be involved in controlling tumour angiogenesis in the pituitary adenomas lacking lymphatic vessels, but may also play a role in starting the process of tumour lymphangiogenesis | Human | VEGFA | 7422 | vascular endothelial growth factor A | An immunohistochemical analysis of VEGF in pituitary adenomas was made Data show a positive relationship between vascular endothelial growth factor expression and hemorrhage in pituitary adenoma |
|